-Bloomberg
Related Posts
Incyte And Syndax Present Additional Data From Positive AGAVE-201 Trial At ASH Plenary Session Showing Axatilimab Efficacy
- Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment
- Data are
Credit Suisse Assumes Sprouts Farmers Market at Neutral, Announces Price Target of $35
Credit Suisse analyst Karen Short assumes Sprouts Farmers Market (NASDAQ:SFM) with a Neutral rating and announces Price Target of $35.
Why Is HCA Healthcare Stock Trading Lower On Friday?
HCA Healthcare's first-quarter results, surpassing revenue and EPS expectations. CEO Sam Hazen emphasizes sustained momentum and volume growth.